Navigation Links
Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
Date:11/15/2010

Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that enhancements in the uptake of adenovectors can be successfully applied to improve the uptake or therapeutic effects of Generx in human patients; that Generx can be successfully advanced in clinical studies outside of the U.S.; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the regulatory or commercialization activities of Generx in the U.S. or other markets; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that ar
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Reports Third Quarter 2010 Financial Results
2. Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean
3. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
4. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
5. GEN reports on the greening of the life sciences
6. Aware, Inc. Reports Second Quarter 2010 Financial Results
7. GEN reports on rediscovered technology to bolster proteomics research
8. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
9. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
10. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... HUNTINGTON, W.Va. The Marshall Institute for Interdisciplinary ... Edwards School of Medicine today announced they will ... develop potential anti-cancer drugs. , Under the agreement ... partners will share the costs and risks of ... also will jointly own any intellectual property and ...
(Date:7/10/2014)... Endomedix, a start-up company housed at NJIT,s business incubator, ... spray-on gel that surgeons will use to staunch bleeding ... onto a surgical site, and the natural bio-polymer solutions ... the patient within 30 seconds. , The gel ... It will translate into less time for the patient,s ...
(Date:7/10/2014)... diseases, such as Alzheimer,s disease, type 2 diabetes, ... common trait that proteins aggregate into long fibers ... have found that neither the amylin monomer precursors ... evidence using two-dimensional infrared (2D IR) spectroscopy has ... pathway that may explain toxicity, opening a window ...
Breaking Biology News(10 mins):Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2New technology reveals insights into mechanisms underlying amyloid diseases 2
... Va. (March 31, 2010) Healthy pre-and ... SE5-OH containing Natural S-equol, a novel soy germ-based ... symptoms, had measures of reproductive hormones that stayed ... safety data were presented at the American Medical ...
... available in Spanish . , Asian wheat may ... varieties against Fusarium graminearum fungi that cause ... Research Service (ARS) plant molecular biologist Guihua Bai, the FHB ... on the Chinese wheat variety Sumai 3 and a few ...
... When David Beckham limped off the pitch, thereby ending ... this summer, sports injuries and rehabilitation techniques were once ... media attention paid to one player,s Achilles tendon is ... as a field of research. Now Paul Comfort and ...
Cached Biology News:Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 2Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 3Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 4Diverse wheat tapped for antifungal genes 2Sports rehabilitation and injury prevention 2
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... According to the International Atomic Energy Agency (IAEA) ... terrorists acquiring sufficient quantities of plutonium or highly ... explosive device. The IAEA also notes that most ... quantities, which can be challenging to detect with ... study appearing this week in the Journal ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2
... Bio-Technology to Present at Rodman and Renshaw,s Annual Global Investment Conference on... -- HARBIN, China, Sept. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
... 7 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... for human disease, announced today that it will be participating ... New York.   Dr. Arthur T. Sands , president and ... on Monday, September 13, 2010 at 10:20 a.m. Eastern Time. ...
... AMLN ) will be presenting at the Morgan Stanley Global ... ET / 7:55 a.m. PT in ... Tuesday, September 14, 2010 at 11:30 a.m. ET / 8:30 ... president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate ...
Cached Biology Technology:Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 2Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 3Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 4Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 5Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 6Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 7Lexicon to Present at Morgan Stanley Global Healthcare Conference 2
MOUSE ANTI RAT RT1Ac Immunogen: PHA activated rat lymphocytes...
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Biology Products: